Journal article

Zoledronic acid does not affect insulin resistance in men receiving androgen deprivation therapy: a prespecified secondary analysis of a randomised controlled trial

AS Cheung, R Hoermann, J Zhu, D Lim Joon, JD Zajac, M Grossmann

Therapeutic Advances in Endocrinology and Metabolism | SAGE PUBLICATIONS LTD | Published : 2021

Abstract

Background: Animal studies suggest that undercarboxylated osteocalcin may improve insulin sensitivity via its effect on testicular testosterone production. Human studies have been conflicting. Men undergoing androgen deprivation therapy (ADT) for prostate cancer experience profound hypogonadism resulting in increased insulin resistance. In a randomised controlled trial (RCT) of zoledronic acid versus placebo in men commencing extended-duration ADT, we aimed to examine the effects on fat mass and glucose metabolism. We hypothesised that zoledronic acid, which reduces osteocalcin concentrations, would worsen ADT-induced insulin resistance. Methods: This was a prespecified secondary analysis of..

View full abstract

Grants

Awarded by National Health and Medical Research Council


Funding Acknowledgements

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was funded by an Australian Government National Health and Medical Research Council (NHMRC) Project Grant (#1062073). Ada Cheung was supported by a NHMRC Medical and Dental Postgraduate Research Scholarship (#1017233), NHMRC Early Career Fellowship (#1143333) and an Endocrine Society of Australia Postdoctoral Award. Mathis Grossmann was supported by a NHMRC Career Development Fellowship (#1024139).